MREO vs. KROS, GLPG, PTGX, EVO, HRMY, NAMS, TARO, ARDX, DVAX, and SNDX
Should you be buying Mereo BioPharma Group stock or one of its competitors? The main competitors of Mereo BioPharma Group include Keros Therapeutics (KROS), Galapagos (GLPG), Protagonist Therapeutics (PTGX), Evotec (EVO), Harmony Biosciences (HRMY), NewAmsterdam Pharma (NAMS), Taro Pharmaceutical Industries (TARO), Ardelyx (ARDX), Dynavax Technologies (DVAX), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical preparations" industry.
Mereo BioPharma Group (NASDAQ:MREO) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, community ranking, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.
In the previous week, Keros Therapeutics had 1 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 3 mentions for Keros Therapeutics and 2 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 1.78 beat Keros Therapeutics' score of 1.10 indicating that Mereo BioPharma Group is being referred to more favorably in the media.
62.8% of Mereo BioPharma Group shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 4.1% of Mereo BioPharma Group shares are owned by insiders. Comparatively, 22.9% of Keros Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Mereo BioPharma Group's return on equity of 0.00% beat Keros Therapeutics' return on equity.
Mereo BioPharma Group has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500.
Mereo BioPharma Group currently has a consensus price target of $6.50, suggesting a potential upside of 84.14%. Keros Therapeutics has a consensus price target of $86.00, suggesting a potential upside of 76.92%. Given Mereo BioPharma Group's higher probable upside, research analysts clearly believe Mereo BioPharma Group is more favorable than Keros Therapeutics.
Mereo BioPharma Group has higher revenue and earnings than Keros Therapeutics.
Keros Therapeutics received 6 more outperform votes than Mereo BioPharma Group when rated by MarketBeat users. However, 72.34% of users gave Mereo BioPharma Group an outperform vote while only 66.67% of users gave Keros Therapeutics an outperform vote.
Summary
Mereo BioPharma Group and Keros Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get Mereo BioPharma Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mereo BioPharma Group Competitors List
Related Companies and Tools
